Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.

Shiraishi Y, Nomura S, Sugawara S, Horinouchi H, Yoneshima Y, Hayashi H, Azuma K, Hara S, Niho S, Morita R, Yamaguchi M, Yokoyama T, Yoh K, Kurata T, Okamoto H, Okamoto M, Kijima T, Kasahara K, Fujiwara Y, Murakami S, Kanda S, Akamatsu H, Takemoto S, Kaneda H, Kozuki T, Ando M, Sekino Y, Fukuda H, Ohe Y, Okamoto I.

Open source

DOI: 10.1016/s2213-2600(24)00185-1
Published: 2024-08-16
Container: Lancet Respir Med
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2213-2600-24-00185-1,
  title = {Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.},
  author = {Shiraishi Y and  Nomura S and  Sugawara S and  Horinouchi H and  Yoneshima Y and  Hayashi H and  Azuma K and  Hara S and  Niho S and  Morita R and  Yamaguchi M and  Yokoyama T and  Yoh K and  Kurata T and  Okamoto H and  Okamoto M and  Kijima T and  Kasahara K and  Fujiwara Y and  Murakami S and  Kanda S and  Akamatsu H and  Takemoto S and  Kaneda H and  Kozuki T and  Ando M and  Sekino Y and  Fukuda H and  Ohe Y and  Okamoto I.},
  year = {2024},
  journal = {Lancet Respir Med},
  doi = {10.1016/s2213-2600(24)00185-1},
  url = {https://doi.org/10.1016/s2213-2600(24)00185-1}
}

RIS

TY  - JOUR
TI  - Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.
AU  - Shiraishi Y
AU  -  Nomura S
AU  -  Sugawara S
AU  -  Horinouchi H
AU  -  Yoneshima Y
AU  -  Hayashi H
AU  -  Azuma K
AU  -  Hara S
AU  -  Niho S
AU  -  Morita R
AU  -  Yamaguchi M
AU  -  Yokoyama T
AU  -  Yoh K
AU  -  Kurata T
AU  -  Okamoto H
AU  -  Okamoto M
AU  -  Kijima T
AU  -  Kasahara K
AU  -  Fujiwara Y
AU  -  Murakami S
AU  -  Kanda S
AU  -  Akamatsu H
AU  -  Takemoto S
AU  -  Kaneda H
AU  -  Kozuki T
AU  -  Ando M
AU  -  Sekino Y
AU  -  Fukuda H
AU  -  Ohe Y
AU  -  Okamoto I.
PY  - 2024
JO  - Lancet Respir Med
DO  - 10.1016/s2213-2600(24)00185-1
UR  - https://doi.org/10.1016/s2213-2600(24)00185-1
ER  -

APA

Y, S., S, N., S, S., H, H., Y, Y., H, H., K, A., S, H., S, N., R, M., M, Y., T, Y., K, Y., T, K., H, O., M, O., T, K., K, K., Y, F., S, M., S, K., H, A., S, T., H, K., T, K., M, A., Y, S., H, F., Y, O., & I., O. (2024). Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.. Lancet Respir Med. https://doi.org/10.1016/s2213-2600(24)00185-1

Source records

europe-pmc · retrieved 2026-09-27T05:07:00.912Z